GC Cell Corp
144510
Company Profile
Business description
GC Cell Corp engages in the provision of anti-cancer immunotherapy. The company is developing an anticancer drug, which is in Phase II clinical trials; and stem cell treatment drugs. It also provides cell banking, sample inspection, clinical trial, and bio logistics services.
Contact
30 beongil to giheung-gu
Gyeonggi
107 Lee Hyun
Yongin16 924
KORT: +82 312609600
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
797
Stocks News & Analysis
stocks
Corning’s AI fiber boom is real, but its stock price may be getting out of hand
Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,935.00 | 14.40 | -0.16% |
| CAC 40 | 8,119.05 | 22.87 | -0.28% |
| DAX 40 | 23,975.08 | 108.45 | -0.45% |
| Dow JONES (US) | 49,167.79 | 62.92 | -0.13% |
| FTSE 100 | 10,326.74 | 5.65 | 0.05% |
| HKSE | 25,679.78 | 245.87 | -0.95% |
| NASDAQ | 24,887.10 | 50.50 | 0.20% |
| Nikkei 225 | 59,917.46 | 619.90 | -1.02% |
| NZX 50 Index | 12,764.40 | 110.54 | -0.86% |
| S&P 500 | 7,173.91 | 8.83 | 0.12% |
| S&P/ASX 200 | 8,710.70 | 10.50 | -0.12% |
| SSE Composite Index | 4,078.64 | 7.71 | -0.19% |